AchE Inhibitor and Insulin
Completed · Phase 1
Conditions studied: Diabetes Mellitus
In brief
The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and insulin secretion response will be evaluated by measuring insulin and glucose at different time points. The test will be carried out twice, once without and once with the administration of a single dose of Pyridostigmine on two separate days. The investigator hypothesizes that inhibiting AChE will potentiate insulin secretion.
Key facts
- Study ID
- NCT03063515
- Run by
- University of Miami
- People needed
- 12
- Starts
- 2017-04-19
- Expected to finish
- 2018-12-14
- Last updated by the study team
- 2019-02-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- 18 years and older
You may not qualify if…
- BMI >30 Kg/m2
- fasting glucose >100
- Glycohemoglobin (Hemoglobin A1C) 5.7% or more
- History of asthma
- Use of medications that may interfere with glucose metabolism
Where it is running
- Diabetes Research Institute — Miami, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.